Nivolumab plus docetaxel in patients with chemotherapy-na ïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial

Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC).

Source: European Journal of Cancer - November 18, 2021 Category: Cancer & Oncology Authors: Karim Fizazi, Pablo Gonz ález Mella, Daniel Castellano, Jose N. Minatta, Arash Rezazadeh Kalebasty, David Shaffer, Juan C. Vázquez Limón, Héctor M. Sánchez López, Andrew J. Armstrong, Lisa Horvath, Diogo A. Bastos, Neha P. Amin, Jia Li, Keziban Unsa Tags: Original Research Source Type: research